Sino Biopharmaceutical Limited
1177
株式のランク
#1750
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
株価
$0.68760349
時価総額
$12.24B
変化（1日）
-0.46%
変化（1年）
-27.78%
国
HK
取引 Sino Biopharmaceutical Limited (1177)
カテゴリー
Healthcare
Sino Biopharmaceutical Limited（1177）の利益
Jun 2026 時点の利益 TTM: $1.21B
Sino Biopharmaceutical Limited の最新の財務報告によると、同社の現在の利益は $1.21B です。2023 年には $764.26M の利益を上げ、これは 2022 年の利益 $756.01M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Sino Biopharmaceutical Limited の利益の推移（2000 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.21B | 66.67% |
| 2024 | $723.03M | -5.40% |
| 2023 | $764.26M | 1.09% |
| 2022 | $756.01M | -74.13% |
| 2021 | $2.92B | 280.79% |
| 2020 | $767.38M | -4.30% |
| 2019 | $801.89M | -51.74% |
| 2018 | $1.66B | 157.64% |
| 2017 | $644.90M | 33.59% |
| 2016 | $482.76M | 8.71% |
| 2015 | $444.09M | 22.80% |
| 2014 | $361.64M | 31.39% |
| 2013 | $275.23M | 19.15% |
| 2012 | $231.00M | 80.70% |
| 2011 | $127.84M | -8.96% |
| 2010 | $140.42M | 36.19% |
| 2009 | $103.10M | 33.11% |
| 2008 | $77.46M | 76.36% |
| 2007 | $43.92M | 66.73% |
| 2006 | $26.34M | 81.55% |
| 2005 | $14.51M | -64.22% |
| 2004 | $40.55M | 81.70% |
| 2003 | $22.32M | 28.38% |
| 2002 | $17.38M | 15.22% |
| 2001 | $15.09M | 37.33% |
| 2000 | $10.99M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $1.35B | 12.01% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -97.81% |
US
|
